Home > Boards > US Listed > Biotechs > Durect (DRRX)

News: $DRRX DURECT Announces Positive Data from its

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 47
Posts 6,144
Boards Moderated 1
Alias Born 06/04/18
160x600 placeholder
DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in ... PR Newswire (US) - 11/12/2019 8:45:00 AM
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results PR Newswire (US) - 11/6/2019 5:47:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 3:37:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:21:37 PM
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs PR Newswire (US) - 11/4/2019 4:05:00 PM
DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4 PR Newswire (US) - 10/30/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2019 1:00:03 PM
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver... PR Newswire (US) - 10/21/2019 10:12:00 AM
DURECT to Present at Two Upcoming NASH Investor Conferences PR Newswire (US) - 10/17/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/7/2019 3:30:55 PM
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Ph... PR Newswire (US) - 10/7/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2019 3:31:06 PM
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIRĀ® for the Treatment of Post-Surgical Pain PR Newswire (US) - 10/2/2019 8:00:00 AM
DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference PR Newswire (US) - 9/26/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 10:48:26 AM
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis PR Newswire (US) - 9/17/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2019 1:37:50 PM
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Ut... PR Newswire (US) - 9/9/2019 9:29:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/6/2019 6:01:44 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/5/2019 2:44:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/4/2019 5:50:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 9/4/2019 5:28:35 PM
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright PR Newswire (US) - 9/4/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2019 4:33:55 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/2/2019 2:32:30 PM
whytestocks Member Level  Tuesday, 09/17/19 11:10:21 AM
Re: None
Post # of 885 
News: $DRRX DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

CUPERTINO, Calif. , Sept. 17, 2019 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists...

In case you are interested DRRX - DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist